xnw5004
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Jul 5, 2021 (NCT06558513)
Timeline
Indications
Studied for
- Carcinoma · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Lymphoma · Phase 1/Phase 2
- Lymphoma, T-Cell, Peripheral · Phase 3
- Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
EZH2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06776952 | Phase 3 | Feb 4, 2025 | Government of China |
| NCT06702605 | Phase 2 | Nov 30, 2024 | Government of China |
| NCT06022757 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2023 | Government of China, Merck |
| NCT06702995 | Phase 1/Phase 2 (Phase 2) | Apr 19, 2023 | Government of China |
| NCT06558513 | Phase 1/Phase 2 (Phase 2) | Jul 5, 2021 | Chinese Academy of Medical Sciences, Government of China |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 5 | 5 | 2 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Merck | For profit | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1